Zytux, Rituximab Biosimilar, May Be Safe, Effective for Hard-to-treat MG
Zytux, a biosimilar of rituximab, may be effective and safe for patients with hard-to-treat myasthenia gravis (MG), a…
Articles by Margarida Maia, PhD
Exercise Program Improved Muscle, Physical Function
Muscle and physical function improved in patients with clinically stable myasthenia gravis (MG) who participated in an individually tailored…
Case Study: COVID-19 May Trigger MG, But Outcomes Can Be Good
An elderly man in India developed generalized myasthenia gravis (MG) after contracting COVID-19, but his condition improved after he…
Thymectomy May Be Better for Early-onset MG
Thymectomy – surgical removal of the thymus gland — may be a better option for treating patients with early-onset non-thymomatous…
Micro RNA Molecule miR-146a May Be Useful Diagnostic Marker
A micro RNA molecule called miR-146a was found at high levels in the blood of patients with myasthenia gravis…
MuSK-MG Tied to Poorer Outcomes in Myasthenic Crisis, Study Reports
Patients with myasthenia gravis (MG) and self-reactive antibodies against the muscle-specific kinase (MuSK) protein are more likely to have…
Plasma Exchange May Be Safe, Effective as Short-term MG Therapy
A new type of plasma exchange treatment, called double-filtration plasmapheresis (DFPP), may be effective and safe for short-term relief of…